Acute liver failure due to drugs

Seminars in Liver Disease

Volumn 28, Issue 2, 2008, Pages 175-187

  Fontana, Robert J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Acute liver failure; Causality assessment; Hepatotoxicity; Idiosyncratic

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ACTIFIED; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANACIN; ANTIHISTAMINIC AGENT; ARTHRITIS FOUNDATION; BUTALBITAL PLUS CAFFEINE PLUS PARACETAMOL; CAPITAL WITH CODEINE SUSPENSION; CHILDREN'S TYLENOL; COLESTYRAMINE; COMTREX; DARVOCET A 500; DARVOCET N 50; DEXTROPROPOXYPHENE NAPSILATE; DIPHENHYDRAMINE; DRIXORAL; ENDOCET; ESGIC PLUS; EXCEDRIN MIGRAINE; FIORICET WITH CODEINE; GOODY'S EXTRA STRENGTH HEADACHE POWDER; HYDROCODONE BITARTRATE PLUS PARACETAMOL; ISOMETHEPTENE MUCATE; ISONIAZID; MAXIDONE; METHYLDOPA; NARCOTIC ANALGESIC AGENT; NITROFURANTOIN; NORCO; NYQUIL; OXYCET; PAMPRIN; PANADOL #3; PANADOL #4; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PERCOCET; PERCOGESIC; PHENAPHEN WITH CODEINE; PHENYTOIN; PLACEBO; PROPYLTHIOURACIL; PROSTAGLANDIN; PSEUDOEPHEDRINE; ROXICET; SEDAPAP; SINEAID; SINUTAB; ST. JOSEPH'S; TETRACYCLINE; THERAFLU; TYLENOL #2; TYLENOL #3; TYLENOL #4; TYLOX; URSODEOXYCHOLIC ACID; VALPROIC ACID; VANQUISH; VICODIN ES; VICODIN HP; WYGESIC; ZYDONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTIFICIAL ORGAN; CLINICAL TRIAL; CONVALESCENCE; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG INDUCED LIVER INJURY; DRUG OVERDOSE; DRUG PACKAGING; EXCHANGE BLOOD TRANSFUSION; HEPATITIS; HISTOPATHOLOGY; HOST SUSCEPTIBILITY; HUMAN; INCIDENCE; LIVER INJURY; LIVER SUPPORT; LIVER TOXICITY; LIVER TRANSPLANTATION; LOADING DRUG DOSE; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; REVIEW; TREATMENT OUTCOME;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; DRUG THERAPY; HUMANS; LIVER; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; OVERDOSE; PROGNOSIS;

EID: 43049139581     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1073117     Document Type: Review

References (115)

1. Centers for Disease Control and Prevention. Nonfatal, unintentional medication exposures among young children: United States 2001-2003. MMWR Morb Mortal Wkly Rep 2006;55(RR-16):1-5
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: an analysis of prospective studies. JAMA 1998;279:1200-1205
3. Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005;33:155-164
4. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-739
5. Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954
6. Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005;33:1-5
7. Meier Y, Cavallaro M, Roos M, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005;61:135-143
8. Duh MS, Walker AM, Kronlund KH Jr. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. Pharmacoepidemiol Drug Saf 1999;8:275-283
9. Beard K, Belic L, Aselton P, et al. Outpatient drug-induced parenchymal liver disease requiring hospitalization. J Clin Pharmacol 1986;26:633-637
10. Galan MV, Potts JA, Silverman AL, Gordon SC. The burden of acute non-fulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005;39:64-67
11. Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic jaundice in the United States? Am J Gastroenterol 2007;102:558-562
12. De Valle MB, Klinteberg AV, Alem N, Olsson R, Bjornsson E. Drug-induced liver injury in a Swedish University hospital outpatient hepatology clinic. Aliment Pharmacol Ther 2006;24:1187-1195
13. Sgro C, Clinard F, Ouazier K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-455
14. Verma A, Lilienfeld DE. The need for a population-based surveillance system for liver disease in the United States. Pharmacoepidemiol Drug Saf 2004;13:821-824
15. Hoofnagle JH. Drug-Induced Liver Injury Network (DILIN). Hepatology 2004;40:773
16. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001;33:308-310
17. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-521
18. Ibanez L, Perez E, Vidal X, Laporte JR. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic disease: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002; 37:592-600
19. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980;92:14-19
20. Lucena MI, Andrade RJ, Fernandez MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006;44:850-856
21. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CF, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33:123-130
22. Graham DJ. Telithromycin and acute liver failure. N Engl J Med 2006;355:2260-2261
23. Gitlin N, Neil JL, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998;129:36-38
24. Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 2000; 95:272-276
25. Molinari M, Watt KDS, Kruszyna T, et al. Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl 2006;12:1892-1895
26. Wai CT, Tan BH, Chan CL, et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int 2007; 27:465-474
27. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007;11:477-505
28. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46: 1323-1330
29. Rockey DC, Seeff LB, Freston JW, et al. Comparison between expert opinion and RUCAM for assignment of causality in drug-induced liver injury [abstract]. Gastroenterology 2007;132:M1777
30. Leeder JS, Xu X, Timsit Y, Gaedigk A. Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions. Pharmacogenetics 1998;8:211-225
31. Aithal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004; 39:1430-1440
32. Sullivan JR, Shear NH. The drug hypersensitivity syndrome: what is the pathogenesis? Arch Dermatol 2001;137: 357-364
33. Neuman MG, Shear NH, Malkiewicz IM, et al. Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides. Transl Res 2007;149:243-253
34. Takikawa H, Takamori Y, Kumagi T, et al. Assessment of 287 Japanese cases of drug-induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol Res 2003;27:192-195
35. Davern TJ, James LP, Hinson JA, et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006;130:687-694
36. James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 2003;31:1499-1506
37. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single-topic clinical research conference. Hepatology 2006;43:618-631
38. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007;6:904-916
39. O'Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000;47:717-720
40. Andrade RJ, Lucena I, Alonso A, et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004;39:1603-1612
41. Pachkoria K, Lucena MI, Ruiz-Cabello F, et al. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol 2007;150:808-815
42. Liu C, Aronow BJ, Jeffa AG, et al. Novel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasis. Gastroenterology 2007;132:119-126
43. Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 2006;44:778-787
44. Watanabe I, Tomita A, Shimizu M, et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2003;73:435-455
45. Kleiner DA, Chalasani NP, Conjeevaram HS, et al. Relationship of biochemical to histologic findings and the pathological pattern of injury among cases identified in the NIH Drug-Induced Liver Injury Network (DILIN) study [abstract]. Gastroenterology 2007;137:M1775
46. Bjornsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007;25:1411-1421
47. Donaldson BW, Gopinath R, Wanless IR, et al. The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators. Hepatology 1993;18:1370-1376
48. Hanau C, Munoz SJ, Rubin R. Histopathological heterogeneity in fulminant hepatic failure. Hepatology 1995;21: 345-351
49. Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007; 35:2498-2508
50. Trey C, Davidson CS. The management of fulminant hepatic failure. Prog Liver Dis 1970;3:282-298
51. Hoofnagle JH, Carithers RL, Shapiro C, et al. Fulminant hepatic failure: summary of a workshop. Hepatology 1995; 21:240-253
52. Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007;26:1429-1435
53. Teo EK, Ostapowicz G, Hussain M, et al. Hepatitis B infection in patients with acute liver failure in the United States. Hepatology 2001;33:972-976
54. Levitsky J, Thadareddy A, Lakeman FD, et al. Quantitative measurement of herpes simplex virus before and after liver transplantation [abstract]. Am J Transplant 2007;7(suppl 2): 1388
55. Lee WM, Brown KE, Young NS, et al. Brief report: no evidence of parvovirus B19 or hepatitis E virus as causes of acute liver failure. Dig Dis Sci 2006;51:1712-1715
56. Umemura T, Tanaka E, Ostapowicz G, et al. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis 2003;188: 1545-1552
57. Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug-induced liver injury in the United States. Liver Transpl 2004;10:1018-1023
58. Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000;31:201-206
59. Mok MY, Ng WL, Yuen MF, et al. Safety of disease-modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000;18:363-368
60. Zachariae H. Liver biopsies and methotrexate: a time for reconsideration? J Am Acad Dermatol 2000;42:531-534
61. Rutherford A, Davern T, Hay JE, et al. Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol 2006;4:1544-1549
62. Lammert C, Bjornsson E, Saha C, et al. Relationship between medication dose and idiosyncratic drug-induced liver injury. Hepatology 2007;46(suppl 1):A1288
63. Squires RH, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the Pediatric Acute Liver Failure Study Group. J Pediatr 2006;148:652-658
64. Lewis JH. "Hy's Law," the "Rezulin Rule," and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 2006;15:221-229
65. Zimmerman HJ. Hepatoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999
66. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42:481-489
67. Ohmori S, Shiraki K, Inoue H, et al. Clinical characteristics and prognostic indicators of drug-induced fulminant hepatic failure. Hepatogastroenterology 2003;50:1531-1534
68. Food and Drug Administration. Guidance for industry: drug-induced liver injury: premarketing clinical evaluation. Fed Regist 2007; October 24
69. O'Grady JG, Alexander GJM, Hayllar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-455
70. Pauwels A, Mostefa-Kara N, Florent C, et al. Emergency liver transplantation for acute liver failure: evaluation of London and Clichy criteria. J Hepatol 1993;17:124-127
71. Bernal W, Donaldson N, Wyncoll D, et al. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002;359:558-563
72. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005;42:1364-1372
73. Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology 2005;41:26-31
74. Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology 2002;36:659-665
75. Makin AJ, Wendon J, Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology 1995;109:1907-1916
76. Constantine JK, Wendon J, Safinia N, et al. Long-term outcomes for patients transplanted for acetaminophen-induced acute liver failure: no worse than for other etiologies [abstract]. Hepatology 2007;46:575
77. Davies MH, Harrison RF, Elias E, Hubscher SG. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol 1994;20:112-116
78. Levy C, Linder KD. Drug-induced cholestasis. Clin Liver Dis 2003;7:311-330
79. Aithal PG, Day CP. The natural history of histologically proved drug-induced liver disease. Gut 1999;44:731-735
80. Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006;44: 1581-1588
81. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-276
82. Bjornsson E, Kalaitzakis E, Av Klintberg V, Alem N, Olsson R. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther 2007;26:79-85
83. Sterling RK, Luketic VA, Sanyal AJ, et al. Treatment of fulminant hepatic failure with intravenous prostaglandin E1. Liver Transpl Surg 1998;4:424-431
84. O'Grady JG, Gimson AE, O'Brien CJ, et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94:1186-1192
85. Demetriou AA, Brown RS, Busuttil RW, et al. Prospective, randomized, multicenter controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004;239:660-667
86. Pohle T, Menzel J, Domschke W. Minocycline and fulminant hepatic failure necessitating liver transplantation. Am J Gastroenterol 2000;95:560-561
87. Furhoff AK. Adverse reactions with methyldopa: a decade's reports. Acta Med Scand 1978;203:425-428
88. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline-induced autoimmune hepatitis and systemic lupus erythematous-like syndrome. BMJ 1996;312:169-172
89. Dechene A, Treicherl U, Gerken G, et al. Effectiveness of a steroid and ursodeoxycholic acid combination therapy with drug-induced subacute liver failure. Hepatology 2005;42: A358
90. Rakela J, Mosley JW, Edwards VM, et al. A double-blinded randomized trial of hydrocortisone in acute hepatic failure. Dig Dis Sci 1991;36:1223-1228
91. European Association for the Study of the Liver Group. Randomized trial of steroid therapy in acute liver failure. Gut 1979;20:620-623
92. Walsh TS, Hopton P, Philips BJ, et al. The effect of n-acetylcysteine on oxygen transport and uptake in patients with fulminant hepatic failure. Hepatology 1998;27:1332-1340
93. Sklar GE, Subramaniam M. Acetylcysteine treatment for non-acetaminophen-induced acute liver failure. Ann Pharmacother 2004;38:498-501
94. Lee WM, Rossaro L, Fontana RJ, et al. Intravenous n-acetylcysteine improves spontaneous survival in early stage non-acetaminophen acute liver failure [abstract]. Hepatology 2007;46:A79
95. Legras A, Bergemer-Fouquet AM, Jonville-Bera AP. Fatal hepatitis with leflunomide and itraconazole. Am J Med 2002; 113:352-353
96. Van Roon EN, Jansen TL, Houtman NM, et al. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 2004;27:345-352
97. Boyer JL. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 2005;129:735-740
98. Zimmerman HJ, Maddrey WC. Acetaminophen hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995;22:767-773
99. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994; 272:1845-1850
100. Schmidt LE, Kalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology 2002;35:876-882
101. Slattery JT, Nelson SD, Thummel KE. The complex interaction between ethanol and acetaminophen. Clin Pharmacol Ther 1996;60:241-246
102. Litovitz TL, Klein-Schwartz W, White S, et al. 2000 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2001;19:337-395
103. Bond GR, Hite LK. Population-based incidence and outcome of acetaminophen poisoning by type of ingestion. Acad Emerg Med 1999;6:1115-1120
104. Nourjah P, Ahmad SR, Karwoski C, Willy M. Estimates of acetaminophen-associated overdoses in the United States. Pharmacoepidemiol Drug Saf 2006;15:398-405
105. Rowden AK, Norvell J, Eldridge DL, Kirk MA. Updates on acetaminophen toxicity. Med Clin North Am 2005;89: 1145-1159
106. Schiødt FV, Rochling FA, Casey DL, et al. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997; 337:1112-1117
107. Lee WM. Acetaminophen toxicity: changing perceptions on a social/medical issue. Hepatology 2007;46:966-970
108. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 2002;40:3-20
109. Myers RP, Li B, Fong A, Shaheen AA, Quan H. Hospitalizations for acetaminophen overdose: a Canadian population-based study from 1995-2004. BMC Public Health 2007;7:143-151
110. Fontana RJ, Adams PC. "Unintentional" acetaminophen overdose on the rise: who is responsible? Can J Gastroenterol 2006;20:319-324
111. Kaplowitz N. Acetaminophen hepatotoxicity: what do we know, what don't we know, and what do we do next? Hepatology 2004;40:23-26
112. Prince MI, Thomas SH, James OF, Hudson M. Reduction in incidence of severe paracetamol poisoning. Lancet 2000; 355:2047-2048
113. Hawton K, Simkin S, Deeks J, et al. UK legislation on analgesic packs: before and after study of long-term effect on poisonings. BMJ 2004;329:1076
114. Food and Drug Administration. 21 CRF Parts 201 and 343. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use: proposed amendment of the tentative final monograph, Required warnings and other labeling. Federal Register Parts 201 and 343 (12/26/06). Available at: http://www.accessdata.fda.gov/scripts/oc/ohrms/frbydocket.cfm
115. Osborne ZP, Bryant SM. Patients discharged with a prescription for acetaminophen-containing narcotic analgesics do not receive appropriate written instructions. Am J Emerg Med 2003;21:48-50